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Abstract 
Both sleep and glutamatergic signaling in the brain are tightly controlled and homeostatically 
regulated. Sleep homeostasis is reliably reflected by predictable changes in brain electrical 
activity in waking and sleep, yet the underlying molecular mechanisms remain elusive. Current 
hypotheses posit that recovery sleep following prolonged waking restores efficient functioning 
of the brain, for example by keeping glutamatergic signaling in a homeostatic range. We 
recently provided evidence in humans and mice that metabotropic glutamate receptors of 
subtype-5 (mGluR5) contribute to the brain's coping mechanisms with sleep deprivation. Here 
we combined in 31 healthy men, proton magnetic resonance spectroscopy to measure the levels 
of glutamate (Glu), GLX (glutamate-to-glutamine ratio) and GABA (γ-amino-butyric-acid) in 
basal ganglia (BG) and dorsolateral prefrontal cortex, simultaneous positron emission 
tomography to quantify mGluR5 availability with the novel radioligand, [18F]PSS232, and 
quantification in blood plasma of the mGluR5-regulated proteins, fragile-X mental retardation 
protein (FMRP) and brain-derived neurotrophic factor (BDNF). All measurements were 
conducted at the same circadian time in baseline, following sleep deprivation and after recovery 
sleep. We found that Glu and GLX in BG (pall < 0.01), but not in prefrontal cortex, and the 
plasma concentration of FMRP (p < 0.02), were increased after sleep loss and tended to 
normalize following recovery sleep (pall < 0.1). Furthermore, a night without sleep enhanced 
whole-brain and striatal mGluR5 availability and was normalized by recovery sleep 
(pall < 0.05). By contrast, other brain metabolites and plasma BDNF levels were not altered. 
The findings demonstrate convergent changes in distinct markers of glutamatergic signaling 
across prolonged wakefulness and recovery sleep in humans. They warrant further studies to 
elucidate the underlying mechanisms that link the homeostatic regulation of sleep and 
glutamatergic system activity in health and disease. 
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Introduction 
Sleep has been conserved throughout evolution and is generally assumed to fulfill vital 
biological functions. This notion is corroborated by the general principle referred to as sleep 
homeostasis, which assumes that the lack of sleep is predictably compensated by increased 
sleep need and intensity as reflected by electroencephalographic (EEG) slow-wave activity 
(SWA; activity in the ~ 0.75-4.5 Hz range) in non-rapid-eye-movement NREM sleep 
(Achermann and Borbély, 2017). Prevailing current hypotheses posit that sleep homeostasis 
serves the normalization of synaptic long-term potentiation (LTP) occurring during 
wakefulness, by synaptic long-term depression (LTD) occurring during NREM sleep 
(Tadavarty et al., 2009; Pigeat et al., 2015; Tononi & Cirelli, 2014). 
Glutamate (Glu) plays an essential role in the fine-tuned molecular processes underpinning 
LTP and LTD (Huber et al., 2002; Marshall, 2006, Kauer and Malenka, 2007). Overstimulation 
of metabotropic and ionotropic Glu receptors by excess extracellular Glu is a major culprit of 
neuronal excitotoxicity and contributes to neuropsychiatric and neurodevelopmental disorders 
that can be exacerbated by inadequate sleep (Sanacora at al., 2008; Ahmed et al., 2011; Averill 
et al., 2017). Suggesting an important contribution of glutamatergic signaling to sleep 
homeostasis and a role for sleep in keeping extracellular Glu in a homeostatic range, Glu levels 
in the frontal cortex of freely moving rats rose during prolonged wakefulness and REM sleep 
and decreased during NREM sleep (Dash et al., 2009). No comparable data are currently 
available in humans. 
Nevertheless, two key players were recently identified that may orchestrate synaptic plasticity 
and glutamatergic signaling across the sleep-wake cycle: Homer1a and metabotropic Glu 
receptors of subtype-5 (mGluR5). Homer1a uncouples mGluR5 from their downstream 
signaling partners, which leads to synaptic LTD (Kammermeier and Worley, 2007; Berridge, 
2016; Ronesi and Huber, 2008). Biochemical, proteomic and imaging studies in mice 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/458885doi: bioRxiv preprint first posted online Oct. 31, 2018; 
4 
demonstrated that Homer1a and signaling from group-I mGluRs (mGluR1/5) drive the 
homeostatic downscaling of excitatory synapses during sleep (Diering et al., 2017). In humans, 
mGluR5 show high expression in brain regions regulating sleep (Hefti et al., 2013) and their 
functional availability was increased after prolonged wakefulness (Hefti et al., 2013). 
Furthermore, increased mGluR5 availability correlated with behavioral and neurophysiological 
markers of elevated sleep need, including self-rated sleepiness, unintended sleep during 
prolonged wakefulness, as well as SWA and slow (< 1 Hz) oscillatory activity in the NREM 
sleep EEG (Hefti et al., 2013; Holst et al., 2017). 
Apart from interacting with Homer1a, activation of mGluR5 regulates the expression of fragile 
X mental retardation protein (FMRP) and brain-derived neurotrophic factor (BDNF), which 
both play important roles in neuronal plasticity (Comery et al., 1997; Huber et al., 2002; Li et 
al., 2002; Restivo et al., 2005; Bramham and Messaoudi, 2005; Desai et al., 2006; Lu et al., 
2014). Work in Drosophila suggested that the dFmr1 gene is a molecular regulator of sleep 
need (Bushey et al., 2009) and that the expression of FMRP controls sleep time and the sleep 
loss-induced sleep rebound (Bushey et al., 2011). Similarly, the expression of BDNF protein 
in mice has been associated with the rebound in SWA following sleep deprivation (Huber et 
al., 2007). Whereas the effects of prolonged waking on the concentration of FMRP in humans 
are unknown, for BDNF either an increase (Schmitt et al., 2016) or a decrease (Kuhn et al., 
2016) have been reported. 
Based upon the evidence outlined above, we simultaneously quantified in healthy human 
volunteers dynamic changes in brain metabolites, including GLX, Glu and GABA (γ-amino-
butyric-acid) in dorso-lateral prefrontal cortex (dlPFC) and basal ganglia (BG), cerebral 
mGluR5 availability, as well as FMRP and BDNF levels in blood serum after prolonged 
wakefulness and following recovery sleep. We hypothesized that sleep loss increases these 
potential markers of elevated sleep need and expected that recovery sleep normalizes the 
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waking induced changes. With the exception of BDNF, all markers quantified revealed the 
expected changes, suggesting that glutamatergic signaling involving mGluR5 importantly 
contributes to the regulation of sleep-wake dependent synaptic plasticity in humans. 
 
Results 
Thirty-one healthy men completed this strictly controlled study (Table 1 for demographics; the 
numbers of study participants contributing to each analysis are specified below). Following 8-
hour adaptation and baseline sleep opportunities in the sleep laboratory, all volunteers stayed 
awake under constant supervision for 40 hours, followed by a 10-hour recovery sleep 
opportunity. All measurements in baseline (BL), after sleep deprivation (SD) and after recovery 
(RE) sleep were conducted at the same circadian time in all three conditions, starting at 4:23 
pm ± 23 min (Fig. 1). 
 
Sleep deprivation increases Glu and GLX levels in the basal ganglia 
Methodological advances in proton magnetic resonance spectroscopy (H1-MRS) have recently 
permitted the non-invasive detection of naturally occurring changes in tightly regulated 
metabolite concentrations in circumscribed areas of the human brain. Whereas one recent study 
suggested that GLX levels in the left parietal lobe decrease over night (Volk et al., 2018), our 
own research revealed no significant changes after sleep deprivation in GLX/Glu and GABA 
in the medial prefrontal cortex (Holst et al., 2017). Thus, the exact roles in humans of the main 
excitatory and inhibitory neurotransmitters in circadian and homeostatic sleep-wake regulation 
remain unclear. Here, we quantified at the same circadian time in 20 study participants the 
effects of prolonged wakefulness and recovery sleep on the extracellular concentrations of Glu, 
GLX and GABA in two predefined voxels located in the cortex (dlPFC) and the BG. Both these 
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regions show pronounced waking-induced changes in mGluR5 availability (Holst et al., 2017) 
and are thought to contribute importantly to sleep homeostasis (Dahan et al., 2006; Léna et al., 
2005; Guillaumin et al., 2018). Consistent with our previous study (Holst et al., 2017), sleep 
deprivation caused no reliable changes in these metabolites in the cortex (Fig. 2, left-hand 
panel). By contrast, Glu and GLX levels in the BG were increased after prolonged waking in 
17 of 20 study participants when compared to baseline (Fig. 2, right-hand panel). The mean 
increase in Glu equaled 6.3 ± 2.06 % (BL: 1.41 ± 0.02 [arbitrary units]; SD: 1.50 ± 0.03; SD 
vs. BL: p < 0.02, Tukey’s test, n = 20). Similarly, sleep loss increased the GLX concentration 
in the BG in 16 of 20 subjects, and the mean increase equaled 9.0 ± 2.53 % (BL: 1.66 ± 0.04; 
SD: 1.81 ± 0.05; SD vs. BL: p < 0.004). Although both, Glu (SD: 1.50 ± 0.03; RE: 1.45 ± 0.03; 
RE vs. SD: 2.8 % reduction) and GLX (SD: 1.81 ± 0.05; RE: 1.73 ± 0.04; RE vs. SD: 4.2 % 
reduction) were slightly reduced after recovery sleep when compared to sleep deprivation, 
these changes did not reach statistical significance. 
The levels of GABA remained stable in the BG following sleep deprivation and recovery sleep 
(BL: 0.45 ± 0.01; SD: 0.45 ± 0.007; SD vs. BL: p >0.8; SD: 0.45 ± 0.007; RE: 0.41 ± 0.01; 
p > 0.05, Tukey’s test, n = 20) (Fig. 2C). 
No significant changes in other metabolites (N-acetylaspartate, glutathione, choline) were 
detected. 
 
Whole-brain mGluR5 availability is elevated after sleep deprivation and normalized after 
recovery sleep 
To quantify sleep-wake associated changes in the availability of mGluR5 that may occur 
simultaneously with the above described local changes in Glu, GLX and GABA, the newly 
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developed, highly selective, non-competitive mGluR5 antagonist for PET brain imaging, 
[18F]PSS232, was employed (Sephton et al., 2014; Warnock et al., 2018). 
When compared to baseline, sleep deprivation induced a consistent increase in whole-brain 
[18F]PSS232 binding potential reflecting elevated cerebral mGluR5 availability (BL: 1.16 ± 
0.04; SD:1.20 ± 0.04; SD vs. BL: p < 0.05, Tukey’s test) (Fig. 3). The [18F]PSS232 binding 
increased from BL to SD in 15 of 20 subjects in whom PET scans in both conditions were 
available. On average, the sleep deprivation-induced increase in whole-brain mGluR5 
availability equaled 5.53± 2.22 %. 
To examine whether recovery sleep reverses the wakefulness-induced changes, PET scans 
were also performed after the recovery night. In 13 of 16 study participants in whom SD and 
RE data were available, whole-brain [18F]PSS232 binding was reduced in RE when compared 
to SD (SD: 1.21 ± 0.05; RE: 1.14 ± 0.04; RE vs. SD: p < 0.01, Tukey’s test). The reduction in 
mGluR5 availability from SD to RE equaled 5.77± 1.50 %. No difference in [18F]PSS232 
binding potential between BL and RE was detected, suggesting that recovery sleep normalized 
the waking-induced enhancement in mGluR5 availability. 
 
Wake-sleep dependent changes in mGluR5 availability in the basal ganglia 
Given the waking-induced increase in Glu and GLX in the BG and the fact that the striatum 
and the amygdala show high mGluR5 expression (Gasparini et al., 2008; Hefti et al., 2013), 
the wake-sleep associated changes in [18F]PSS232 binding were quantified specifically in 
caudate nucleus, putamen and amygdala. A pronounced increase in mGluR5 availability after 
prolonged waking was confirmed in all three regions (caudate nucleus: BL: 1.15 ± 0.06; SD: 
1.25 ± 0.06; increase: 8.7 ± 4.8 %; SD vs. BL: p < 0.03; putamen: BL: 1.18 ± 0.05; SD: 1.20 ± 
0.05; increase: 5.41 ± 2.42 %; SD vs. BL: p < 0.2; amygdala: BL: 1.27 ± 0.07; SD: 1.38 ± 0.07; 
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increase: 8.6 ± 4.72 %; SD vs. BL: p < 0.03, Tukey’s tests, n = 20) (Fig. 4). Similar to the 
whole-brain data, recovery sleep normalized mGluR5 availability in caudate nucleus (SD: 1.25 
± 0.06; RE: 1.14 ± 0.06; reduction: 8.59 ± 3.46 %; RE vs. SD: p < 0.02), putamen (SD: 1.23 ± 
0.05; RE: 1.16 ± 0.05; reduction: 6.09 ± 2.65 %; RE vs. SD: p < 0.02) and amygdala (SD: 1.38 
± 0.07; RE: 1.23 ± 0.07; reduction: 11.31 ± 4.71 %; RE vs. SD: p < 0.01, Tukey’s tests, n = 16) 
to the level of baseline (RE vs. BL: pall > 0.5, Tukey’s test, n = 16) (Fig. 4). 
 
Sleep deprivation increases FMRP concentration in blood serum 
To tackle the question whether the wake-sleep-related changes in Glu/GLX concentrations and 
mGluR5 availability in the brain are mimicked by changes in mGluR5-regulated proteins in 
peripheral blood, circulating FMRP and BDNF in serum were quantified with enzyme-linked 
immunosorbent assays (ELISA) in BL, SD and RE conditions. Intriguingly, prolonged waking 
increased blood FMRP concentration by 25.86 ± 16.39 % (BL: 268.52 ± 33.76 pg/ml; SD: 
370.86 ± 31.93 pg/ml; SD vs. BL: p < 0.02, n = 23) (Fig. 5). Although the FMRP concentration 
tended to revert to baseline, the values in SD and RE conditions were not significantly different 
(SD: 370.86 ± 31.93 pg/ml; SD: 333.89 ± 33.51 pg/ml; RE vs. SD, p > 0.6). In contrast to 
FMRP, the levels of BDNF were not affected by prolonged waking nor recovery sleep 
(supplementary Figure S2). 
 
Discussion 
Glutamate is the primary excitatory neurotransmitter of the human brain. Although basic 
research in vitro and in animal models highlights a prominent role for glutamatergic 
mechanisms in regulating sleep-wake homeostasis (Maret et al., 2007; Dash et al., 2009; 
Ahnaou et al., 2015; Diering et al., 2017; Holst et al, 2017; for review, see Halassa & Haydon, 
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2010), knowledge about glutamatergic signaling as a function of waking and sleep in humans 
is scarce. Here we investigated the effects of prolonged wakefulness and recovery sleep on 
simultaneous changes in upstream and downstream molecular markers of metabotropic 
glutamatergic neurotransmission in healthy adults. We found that one night without sleep 
elicited reliable increases in cerebral Glu/GLX levels and mGluR5 availability, particularly in 
the basal ganglia, as well as in the concentration of the mGluR5-regulated protein, FMRP, in 
the blood stream. Given that these wakefulness-induced molecular changes tended to normalize 
after recovery sleep, the findings suggest that sleep is essential to keep glutamatergic signaling 
in a homeostatic range. Furthermore, the study indicates that human sleep may counteract 
neuronal dysfunction and degeneration, which can be caused by excessive glutamate (Sanacora 
at al., 2008; Ahmed et al., 2011; Averill et al., 2017), on multiple levels of the metabotropic 
glutamatergic signaling cascade. 
 
Sleep deprivation and recovery sleep induce dynamic changes in basal ganglia glutamate 
levels 
The levels of glutamate in the rat cortical extra-synaptic space rise during waking and decrease 
during NREM sleep (Dash et al., 2009), yet it is currently unknown whether similar changes 
also occur in the human brain. To examine a glutamatergic contribution to the relief of 
depressive symptoms after wake therapy, brain levels of Glu, GLX and GABA were previously 
measured with 1H-MRS in depressed patients undergoing acute and repeated therapeutic sleep 
deprivation (Murck et al., 2002; Murck et al., 2009; Benedetti et al., 2009). No significant 
alterations in GLX or its elements were found in different cortical regions (dlPFC, anterior 
cingulate cortex and parieto-occipital cortex), yet preliminary data indicated that sleep loss 
increased GLX in subcortical brain regions (Murck et al., 2002). Because the baseline levels 
of GLX and Glu in cerebral cortex differ between depressed patients and healthy controls 
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(Järnum et al., 2011; Njau et al., 2017), it is unclear whether these older studies are directly 
comparable with the present investigation. Nevertheless, our previous (Holst et al., 2017) and 
current work in healthy controls is consistent with the data in depressed patients (Benedetti et 
al., 2009; Murck et al., 2009). It indicates that prolonged wakefulness does not reliably alter 
the MRS signal compatible with GLX and its constituents in anterior cingulate cortex and 
dlPFC. It cannot be excluded, however, the lack of a significant change in GLX in the dlPFC 
voxel could be related to the voxel composition, which, compared to the basal ganglia voxel 
was composed of a higher fraction of grey matter. 
The data collected in the BG strongly suggest that sleep loss indeed affects glutamatergic 
signaling on different levels. More specifically, prolonged wakefulness increased Glu, GLX 
and mGluR5 availability in sub-regions of the basal ganglia, and these changes were re-
normalized after recovery sleep. The findings corroborate and expand previously published 
observations from our group, showing that mGluR5 availability was increased after sleep 
deprivation (Hefti et al., 2013). Importantly, the new data demonstrate that recovery sleep is 
associated with reduced mGluR5 availability, supporting a restorative role for sleep and 
providing complementary evidence for the mGluR5 signaling cascade to contribute to sleep-
wake regulation. The investigation of different brain regions indicated that the basal ganglia 
are a brain structure that reliably shows sleep-wake related changes in the glutamatergic 
balance in humans. The dorsal (caudate nucleus and putamen) and ventral (nucleus accumbens 
and olfactory tubercle) parts of the striatum and the amygdala showed increased mGluR5 
availability after sleep loss (Hefti et al., 2013; supplementary material). The data strengthen 
the emerging hypothesis that the basal ganglia are a key player in sleep-wake regulation 
(Lazarus et al., 2013; Holst & Landolt, 2015; Holst & Landolt, 2018). Whereas each, the 
increase in Glu levels and mGluR5 availability after extended wakefulness equaled roughly 5-
10 % and may be considered as small or moderate, the simultaneous changes could mutually 
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amplify each other and cause a substantial increase in glutamatergic signaling after sleep 
deprivation. 
 
Sleep deprivation impacts on the expression of FMRP 
Currently the most specific molecular marker of sleep need is the immediate early gene 
Homer1a (Maret et al., 2007; Mackiewicz et al., 2008) which uncouples mGluR5 from its 
downstream signaling partners, leading to synaptic long-term depression (Kammermeier and 
Worley, 2007; Ménard and Quirion, 2012; Berridge, 2016; Diering et al., 2017; Ronesi and 
Huber, 2008). This form of synaptic plasticity may ultimately support sleep dependent recovery 
processes (Diering et al., 2017; Krueger et al., 2013; de Vivo et al., 2017). The mGluR5 has 
been specifically associated with two proteins that may be important for sleep-wake regulation: 
FMRP and BDNF. Consistent with experiments in Drosophila (Bushey et al., 2009), we found 
elevated FMRP levels after prolonged wakefulness when compared to baseline. A prolonged 
effect of sleep deprivation might explain the delayed normalization after recovery sleep. In 
contrast to the findings in vivo, the FMRP concentration in cultured neural cells of sleep 
deprived rats appeared to decrease with sleep deprivation (Kwon et al., 2015). Thus, further 
research is needed to clarify the potential role for FMRP in sleep-wake regulation. Similarly, 
the evidence for a suggested role of BDNF in regulating sleep homeostasis and LTP-like 
plasticity after sleep deprivation (Faraguna et al., 2008; Kuhn et al., 2016) has been equivocal. 
Here, neither sleep deprivation nor recovery sleep revealed consistent effects on BDNF levels 
in the human serum as quantified with ELISA. The establishment of a reliable method to assess 
blood serum BDNF still remains a clinical challenge. The discrepancies among the available 
studies may reflect the methodological difficulties in the reliable quantification of BDNF serum 
concentration. 
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Taken together, our study provides convergent evidence that sleep deprivation and recovery 
sleep affects glutamatergic signaling in distinct regions of the human brain that play an 
important role in sleep-wake regulation. Nevertheless, the questions remain whether the 
observed molecular changes regulate the need for sleep or whether they reflect secondary 
changes associated with the expression of wakefulness and sleep, or both. The present findings 
warrant further studies to elucidate the mechanisms that link the homeostatic regulation of sleep 
and glutamatergic system activity in health and disease. 
 
Materials and Methods 
To visualize the interplay of mGluR5 with its potential molecular signaling partners in sleep-
wake regulation, a controlled in-lab study was designed, in which 3-Tesla PET/MR-
Spectroscopy scanning and blood sampling were conducted three times, at the same circadian 
time in baseline, after 40 hours prolonged waking, and again following recovery sleep. mGluR5 
availability was quantified with the novel PET radioligand [18F]PSS232 which is a non-
competitive selective antagonist of mGluR5 (Sephton et al., 2014; Warnock et al., 2018). 
Concentrations of glutamate, the glutamate/glutamine (GLX) ratio and γ-amino-butyric acid 
(GABA) in basal ganglia (BG) and dorsolateral prefrontal cortex (dlPFC) were measured with 
dedicated PRESS/MEGAPRESS MRS sequences. Circulating levels of BDNF and FMRP in 
human blood were quantified with ELISA. 
 
Study Participants 
The study protocol and all experimental procedures were approved by the ethics committee of 
the Canton of Zürich for research on human subjects. All subjects provided written informed 
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consent prior to the experiments and received financial compensation for their participation, in 
accordance with the principles in the Declaration of Helsinki. 
Thirty-one healthy men completed a within subject design 1-week sleep deprivation protocol 
after being screened for medical history and psychological state. All subjects were non-
smokers, in good health, had no history of neurologic or psychiatric disease and were instructed 
not to take any medications or consumed any illicit drugs 2 months prior to the study. Subjects 
were excluded if they traveled across multiple time zones or performing shift work 3 months 
prior to study participation. Subjects with unknown sleep disturbances, such as sleep apnea, 
sleep efficiency < 75% or periodic leg movements during sleep (PLMS) with an index of 5 or 
more per hour of sleep were excluded from participation based on polysomnographic screening 
in the sleep laboratory before enrolment. Table 1 summarizes lifestyle and demographic 
characteristics of the healthy study sample assessed by validated questionnaires. 
Thirty-one healthy male participants, ten of which were between 60 to 70 years of age, 
completed the study protocol. Validated German translations and versions of questionnaires 
were used to assess lifestyle and personality traits. Caffeine consumption was calculated based 
on the following amounts per serving: coffee: 100mg; ceylon or green tea: 30 mg; cola drink: 
40 mg (2 dL); energy drink: 80 mg (2 dL); chocolate: 50 mg (100 g). Diurnal preference: 
Horne-Östberg Morningsness-Eveningness Questionnaire (Horne et al., 1976); daytime 
sleepiness: Epworth Sleepiness Scale (Bloch et al., 1999); depression score: Beck Depression 
Inventory (Beck et al., 1961); personality traits: Eysenck Personality Questionnaire (Francis et 
al., 2006); cognitive assessment: Montreal Cognitive Assessment (Nasreddine, 2005); trait 
anxiety: State-Trait Anxiety Inventory (Spielberger et al., 1970); sleep quality: Pittsburgh 
Sleep Quality Index (Buysse et al., 1989). 
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Pre-experimental Procedure and Experimental Protocol 
Two weeks prior to the study, participants were required to refrain from all sources of caffeine 
and wear a wrist activity monitor on the non-dominant arm. During the 5 days prior to the study 
they were asked to abstain from alcohol intake and to maintain a regular 8-hour night-time 
sleep schedule, corresponding approximately to the participants’ habitual sleep times. Daily 
log-books and wrist actigraphy verified compliance with the pre-study instructions. 
Additionally, caffeine and ethanol concentrations in saliva and breath were tested upon entering 
the laboratory, to confirm participants’ abstinence. 
Under constant supervision, all subjects completed a within-subject sleep deprivation protocol 
(Figure 1), consisting of an 8 hours adaptation and baseline night (time in bed: 11:00PM-
07:00AM), followed by 40 hours of continuous wakefulness, and terminated by a 10 hour 
recovery night. In baseline, sleep deprivation and recovery condition, twenty-two subjects 
underwent a combined positron emission tomography (PET) and magnetic resonance 
spectroscopy (MRS) examination at the same circadian timepoint (4:23PM ± 23 min) with 
[18F]PSS232 to quantify mGluR5 availability in the brain (Division of Nuclear Medicine, 
University Hospital Zürich). Due to time and logistic constraints, only two subjects could be 
PET scanned per experimental week. To optimize data collection, one additional subject was 
included in each study block (9 in total) as a back-up candidate, participating in the entire 
experimental protocol, MR imaging and blood sampling, but without the [18F]PSS232 injection 
and PET scan. 
 
Magnetic Resonance Spectroscopy data acquisition and analysis 
Magnetic resonance spectroscopy data were acquired simultaneously with the PET data using 
a GE 3T combined PET/MR scanner (SIGNA PET/MR; GE Healthcare). Single-voxel edited 
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1H-MR spectra were acquired from two voxels of interest in the left dorsolateral prefrontal 
cortex (dlPFC; 30 x 25 x 40 mm3) and in the basal ganglia (BG; 25 x 25 x 25 mm3) using the 
Point RESolved Spectroscopy (PRESS) and MEGAPRESS methods. In addition, a third VOI 
in the BG (25 x 30 x 35 mm3) was measured with the MEGAPRESS method (Mescher et al., 
1998) to specifically quantify GABA. To ensure a consistent MRS voxel position between 
subjects, the voxel was carefully positioned based on anatomical landmarks on the T1 image. 
The T1 weighted MR images were also used to correct for partial volume effects related to the 
CSF content in the MRS voxel, as well as for gray/white matter correction. 
MEGAPRESS: A total of 320 spectra were averaged to obtain the final spectrum. Individual 
spectra were acquired with a TR of 1800 ms, an echo time of 68 ms, and an eight-step phase 
cycle, resulting in a total acquisition time of ~10 minutes. For each metabolite spectrum, 16 
water reference lines were also acquired as part of the standard PROBE acquisition. 
PRESS:  The PRESS spectra were acquired with an echo time (TE) of 35 ms and a repetition 
time (TR) of 3 ms. 160 spectral averages were acquired to obtain the final spectrum resulting 
in an acquisition time of 9 min. 
 
Data analysis 
MR spectra were analyzed with LCModel v. 6.3-1 (Provencher 1993), which is a fully 
automated spectral fitting method. For the MEGAPRESS data, edited spectra were analyzed 
with a simulated basis set providing metabolite concentrations for glutamine (Gln), glutamate 
(Glu), glutamate to glutamine (GLX), GABA, N-acetylaspartate, and glutathione. The control 
parameter sptype = ‘megapress-2’ was used to avoid mis-assignment of the baseline to GABA. 
For the PRESS spectra, a standard experimental basis set was used, from which data for 
creatine, glutamate to glutamine, myo-inositol, N-acetylaspartate, and total choline were 
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extracted (Supplementary Figure S1). For all spectra, peaks that were poorly fitted, resulting 
in Cramer-Rao minimum variance bounds of more than 20 % as reported by LCModel, were 
excluded from further analyses. 
 
PET Image Acquisition 
A T1-weighted, whole-brain, three-dimensional magnetic resonance (MR) image (resolution: 
1 x 1 x 1 mm) was obtained for each subject in parallel to the PET imaging (SIGNA PET/MR 
3T whole-body PET/MR unit equipped with an 8-channel head coil; GE Healthcare), to 
exclude morphological abnormalities and as anatomical standard for the quantification of the 
PET images. After an automated standard single bolus injection of [18F]PSS232, dynamic PET 
brain imaging was performed for 60 min. Images were acquired in 3D Mode with Time of 
flight fully iterative reconstruction (VPFX) using standard MRAC based attenuation correction 
with a resolution of 1.17 x 1.17 x 2.78 mm3 and Matrix size of 256 x 256 x 89 voxels binned 
into 43 timeframes (11 x 1 min, 22 x 2 min, 10 x 1 min). Subjects were instructed to not fall 
asleep during image acquisition. To verify wakefulness, subjects were instructed to gently press 
the button of a response box, generating as little movements as possible. As soon as subjects 
stopped pressing the response box, subjects were alerted via an intercom. Direct contact was 
avoided, to minimize movement artifacts. 
Injected activity (baseline: 164.7 ± 24.5 MBq; sleep deprivation: 159.1 ± 15.9 MBq; recovery: 
154.7 ± 12.9 MBq) did not differ between the conditions (pall > 0.45; two-tailed, paired t tests). 
 
Image processing and quantification 
All processing and quantification analyses were conducted with a dedicated brain PET/MR 
analysis tool (PNEURO, version 3.7) provided by PMOD Technologies LLC. PET image 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/458885doi: bioRxiv preprint first posted online Oct. 31, 2018; 
17 
processing consisted of within-subject rigid-body motion correction followed by time-series 
alignment to the MR-T1 image for between scan comparisons. For PET quantification, the T1 
image was automatically segmented, separating the MR image into gray matter (GM), white 
matter (WM) and cerebrospinal fluid (CSF) probability maps. After matching the T1 MR image 
to the functional PET images, the specific neocortical and subcortical (core brain segments) 
brain regions were determined using the Hammers-N30R83 brain atlas. Partial volume 
correction (PVC) was performed automatically in the PNEURO toolbox. A time activity curve 
(TAC) was calculated for each VOI. Because a single bolus injection was used, the binding 
potential (BPnd) was quantified with standard SRTM2 [Simplified Reference Tissue Model 
with fixed k2; (Wu & Carson, 2002)] modelling. For modelling, TACs of receptor-rich regions 
(gray matter VOIs) were compared to the TAC of a receptor-less region (cerebellum) believed 
mainly to entail non-specific binding (Warnock et al., 2018). 
 
Assessment of proteins from human serum 
Fresh blood was collected immediately before the PET/MRS scans in two 10ml cloth activator 
tubes (BD Vacutainer® CAT). The samples were allowed to cloth for about 30 minutes at room 
temperature (RT) before centrifugation (2.000 relative centrifugal force (RCF) for 10 min). 1.9 
mL serum was extracted and purified by a second centrifugation step (12.000 RCF for 5 
minutes). The purified serum was aliquoted into multiple 255μ1 samples and stored in 
Eppendorf tubes (SafeSeal micro tube 1.5ml, PP, Sarstedt, Nümbrecht) The probes were then 
snap-frozen in liquid nitrogen and stored at -80°C for future analysis. 
 
Fragile X mental retardation protein (FMRP) 
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FMRP was studied by a quantitative sandwich enzyme-linked immunosorbent assay (ELISA) 
purchased prefabricated and ready to use (Human Fragile X mental retardation 1 ELISA kit, 
MyBioSource, San Diego, California USA). The detection rate of this assay is 15.6– 1000 
pg/ml. A 96-well microplate was pre-coated with a FMRP-specific antibody. Each sample was 
quantified at least twice for independent confirmation. The assay was performed according to 
the manufacturer’s instructions and guidelines. 
 
Brain-derived neurotrophic factor (BDNF) 
Quantification of serum BDNF levels was conducted at the Department of Clinical Psychology 
and Psychotherapy at the University of Zurich using a 96-Well MULTI-ARRAY® BDNF 
Assay purchased from Meso-Scale Discovery (MSD®, Rockville, Maryland USA). The 
analysis was performed according to the manufacturer’s instruction. 
 
Statistical Analyses 
All statistical analyses were performed with SAS 9.4 software (SAS Institute, Cary, North 
Carolina). If not stated otherwise, numbers represent mean ± standard error of the mean (SEM). 
Only significant results are reported. Following standards, the error bars shown in the figures 
represent the SEM of between-subjects variability. Mixed-effect repeated measure analysis of 
variance included the factors ‘condition’ (baseline, sleep deprivation, recovery). Analyses of 
PET data were limited to the predefined VOIs and strictly statistically corrected as follows: 1. 
Comparisons of the mixed effect factor ‘condition’ for each VOI were post-hoc corrected 
(Tukey-Kramer correction: α < .05). 2. Corrected Tukey-Kramer p-values across all 
investigated VOIs were additionally corrected using false discovery rate correction [(FDR): α 
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< .05]. Following significant main effects or interactions, Mann-Whitney U testing was 
employed to illustrate individual differences. 
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Table 1. Demographic Data of Study Participants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values represent means ± SEM (n = 31). Caffeine consumption was calculated based on the 
following amounts per serving: coffee: 100mg; ceylon or green tea: 30 mg; cola drink: 40 mg 
(2 dL); energy drink: 80 mg (2 dL); chocolate: 50 mg (100 g). Diurnal preference: Horne-
Östberg Morningsness-Eveningness Questionnaire (Horne et al., 1976); daytime sleepiness: 
Epworth Sleepiness Scale (Bloch et al., 1999); depression score: Beck Depression Inventory 
(Beck et al., 1961); personality traits: Eysenck Personality Questionnaire (Francis et al., 2006); 
cognitive assessment: Montreal Cognitive Assessment (Nasreddine, 2005); trait anxiety: State-
Trait Anxiety Inventory (Spielberger et al., 1970); sleep quality: Pittsburgh Sleep Quality Index 
(Buysse et al., 1989). 
 
 
Mean ± SD 
Age (Years) 41.44 ± 20.86 
Body Mass Index (kg/m2) 23.85 ± 2.37 
Caffeine Consumption (mg/day) 176.32 ± 144.64 
Alcohol Consumption (Drinks/Week) 2.98 ± 2.67 
Daytime Sleepiness  7.14 ± 3.27 
Habitual Sleep Duration (min) 446.59 ± 32.71 
Sleep Quality 3.05 ± 1.46 
Diurnal Preference  56.00 ± 10.31 
Trait Anxiety  29.68 ± 7.55 
Eysenck Personality Traits 
 
 Psychoticism 1.95 ± 1.68 
 Extraversion 7.32 ± 3.40 
 Neuroticism 2.18 ± 2.68 
 Lie scale 3.68 ± 2.51 
Depression Score  3.45 ± 4.64 
Cognitive Assessment  29.14 ± 1.04 
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Figure legends 
Figure 1. Experimental protocol. After an adaptation and baseline night, subjects underwent 
40hrs of prolonged wakefulness followed by a recovery night. At baseline (BL), after sleep 
deprivation (SD), and again after recovery sleep (REC), levels of mGluR5 were measured using 
positron emission tomography with [18F]PSS232 at the same circadian timepoint (blue dotted 
lines). Furthermore, distinct brain metabolites were measured with magnetic resonance 
spectroscopy and blood samples for the quantification of blood BDNF and FMRP levels were 
drawn at these timepoints. Blue box summarizes type of data collection and number of subjects 
at the imaging sessions in BL, SD and REC conditions (blue dotted lines). A cognitive test 
session was performed every three hours of wakefulness consisting of vigilance (Psychomotor 
Vigilance Task (PVT); Dinges et al., 1985), sleepiness (Karolinska Sleepiness Scale (KSS); 
Akerstedt et al., 1990), tiredness symptoms (Tiredness Symptoms Scale (TSS); Schulz et al., 
1991) and affective state (Visual Analogue Scales (VAS); Hoddes et al., 1973) testing. 
 
Figure 2: Effects of sleep deprivation and recovery sleep on endogenous brain metabolites 
in dorsolateral prefrontal cortex (left) and basal ganglia (right). Magnetic resonance 
spectroscopy yielded levels of glutamate (Glu; A), glutamate/glutamine ratio (Glx; B) and γ-
aminobutyric acid (GABA; C) relative to creatine in baseline (BL, dark grey), sleep deprivation 
(SD, blue) and recovery (RE, light grey) conditions. Data represent means of arbitrary units 
(A.U.) ± standard error of the mean (SEM) in N=31. Black dots represent individual subjects. 
Data for Glu and Glx were acquired with PRESS and data for GABA with MEGAPRESS 
sequences. BG: Mixed-model ANOVA with factor ‘condition’: Glu - F2,36 = 4.83, p < 0.05; 
GLX - F2,36=6.32, p < 0.01; GABA - F2,36 = 4.71, p < 0.02. 
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Figure 3: Effects of sleep deprivation and recovery sleep on metabotropic glutamate 
receptor subtype 5 availability. (A) Global NonDisplaceable binding potential (BPND) after 
[18F]PSS232 uptake in human brain. Columns display global mGluR5 availability in the human 
brain in baseline (BL, dark grey), sleep deprivation (SD, red) and recovery (RE, light grey) 
conditions. Data represent means + standard error of the mean (SEM) in N=22 in baseline, 
N=20 in sleep deprivation and N=18 in recovery condition. (mixed-model ANOVA, factor 
‘condition’: F2,36=4.52, p<0.05) (B) Box plots illustrate the calculated increase of global 
mGluR5 availability in percent after sleep deprivation (SD vs. BL), the calculated decrease 
after recovery sleep (RE vs. SD) and in addition the difference between baseline and recovery 
conditions (RE vs. BL). Black dots represent individual subjects. Asteriks indicate significant 
increase or decrease in change scores (Mann-Whitney U tests: * = p < 0.05; ** = p < 0.01). 
Figure 4: Regional differences in the effect of sleep deprivation and recovery sleep on 
metabotropic glutamate receptor subtype 5. Top: NonDisplaceable binding potential (BPND) 
after [18F]PSS232 uptake in Caudate Nucleus (A), Putamen (B) and Amygdala (C). Columns 
display global mGluR5 availability in the human brain in baseline (BL, dark grey), sleep 
deprivation (SD, red) and recovery (RE, light grey) conditions. Data represent means + 
standard error of the mean (SEM) in N=22 in baseline, N=20 in sleep deprivation and N=18 in 
recovery condition. (mixed-model ANOVA, factor ‘condition’ Caudate Nucleus: 
F2,36=6.25, p<0.01; Putamen: F2,36=4.61, p<0.05; Amygdala: F2,36=5.54, p<0.01) Bottom: 
Box plots illustrate the calculated increase of mGluR5 availability in percent in Caudate 
Nucleus (A), Putamen (B) and Amygdala (C) after sleep deprivation (SD vs. BL), the 
calculated decrease after recovery sleep (RE vs. SD) and in addition the difference between 
baseline and recovery conditions (RE vs. BL). Black dots represent individual subjects. 
Asteriks indicate significant increase and decrease in change scores (Mann-Whitney U tests: 
* = p < 0.05; ** = p < 0.01). 
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Figure 5: Effects of sleep deprivation and recovery sleep on blood fragile X mental 
retardation protein levels. (A) Circulating human blood levels of FMRP in pg/mL. Columns 
display amounts of FMRP in baseline (BL, dark grey), sleep deprivation (SD, red) and recovery 
(RE, light grey) conditions. Data represent means + standard error of the mean (SEM) in N=24 
in baseline, N=27 in sleep deprivation and N=26 in recovery condition. Mixed model ANOVA 
main effect of ‘condition’: F2, 44 = 3.37, p < 0.05. (B) Box plots illustrate the calculated 
increase of blood FMRP levels in percent after sleep deprivation (SD vs. BL), the calculated 
decrease after recovery sleep (RE vs. SD) and in addition the difference between baseline and 
recovery conditions (RE vs. BL). Black dots represent individual subjects. 
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